



ESLAV/ ECLAM Winter School: Final programme

Day 1

COMPARATIVE PHYSIOPATHOLOGY - species differences, do they matter?

10am/5pm

Choice of animal species for regulatory toxicology in pharmaceutical development

Jaynes Harris, AstraZeneca

Use of preclinical species to inform human pharmacokinetics in drug development

Christina Chan, AstraZeneca

The immune system: friend or foe in model selection?

Richard Haworth, RosettaPath

Comparative pathology

Naylor Stuart, Charles River Laboratories

Target organ toxicity in non-clinical toxicology studies; relevance to humans?

Jacobsen Matthew, AstraZeneca

Day 2

IN VIVO MODEL SELECTION

9am/5pm

Choice of animal models for CNS trauma - Translational and Welfare considerations in animal models for CNS Trauma

Jordi Tremeloda, Univesrity of London

Behavioural studies in rhesus monkeys: reinforcement learning and economic choice

Wolfram Schultz, University of Cambridge

Animal Models in Drug Discovery: Translatability to Human Oncology

Natalie Burrows, AstraZeneca

How are in vivo models used to support drug discovery and development in early respiratory and immunology'?

Dom Corkill, AstraZeneca

Mouse Model Selection for Acute Kidney Injury (AKI) or Chronic Kidney Disease (CKD)

Federica Petrillo, AstraZeneca

Day 3

NEW APPROACH METHODOLOGIES (NAMs) - and role of the veterinarians going forward.

9am/4pm

Implementing advanced cell models into pre-clinical assessment: successes, challenges, and opportunities

Rhiannon David, AstraZeneca

The importance of organoids in pre-clinical studies

Sarah Consonni, AstraZeneca

NAMs for safety risk assessment - MPS

Kainat Khan, AstraZeneca

Novel advanced cell models for translational hepatic safety

Dom Williams, AstraZeneca

Animal-free media and reagent, title TBC

Jonathan Sheard, UPM

Application of OMICs for predictive toxicology

Kevin Moreau, AstraZeneca

Mathematical modelling enables the translation of in vitro drug toxicity into clinical outcomes

Carmen Pin, AstraZeneca

Can artificial intelligence replace animal testing?

Nowojewski Andrzej, AstraZeneca